About CCAB

The Centre for the Commercialization of Antibodies and Biologics (CCAB) translates early stage biologics into high-value assets and products. Our Partners can access a robust portfolio of validated antibodies and biologics, powered by the University of Toronto’s antibody discovery engine, the Toronto Recombinant Antibody Centre (TRAC).

Work with us to access world-class expertise, a state-of-the-art phage display discovery platform, established antibody libraries and validated screening technologies.

From discovery and development to validation and licensing, CCAB reduces the time, risk, and costs associated with bringing new antibodies to market.

Our Purpose – What we do

CCAB provides in-house expertise in biotechnology business development and leverages the critical skills, expertise and infrastructure developed within TRAC and its network of collaborative scientists to rapidly translate inventions toward achieving a real impact within the healthcare system and the broader scientific research community.

With our in-house development of therapeutic, diagnostic, and reagent antibodies, and its support of startup companies in these areas, CCAB’s mission is to:

  • Develop novel medicines that will improve the lives of patients, within Canada and globally
  • Provide new tools and tests that will advance medical research and our understanding of diseases
  • Help create new companies to build and sustain Canada’s life Sciences and biotechnology sector
  • Stimulate increasing international partnerships and investment in Canada’s Life Sciences and Biotechnology sector

 

Our Vision – What we see ahead

The research group of our CEO, Dr. Sachdev Sidhu, is using phage display technology and protein engineering to produce antibodies and other biologics. This has led to the formation, in 2014, of Northern Biologics, an antibody development company specializing in oncology and fibrosis targets. In 2015, Ubiquitech, Inc. was launched to develop and commercialize protein-modulating biologics based on the ubiquitin scaffold. Both companies are based in Toronto, and as CCAB grows, we will build and support the growth of Toronto’s biotech community with additional startups rooted in our antibodies and biologics.

 

Our Story – Where we began

In the past decade, recombinant antibody technology has undergone dramatic advances and now represents a major driving force in the development of new targeted therapies against cancer and other devastating diseases. The use of antibodies in medical diagnostics and as probes to understand cell biology and pathology also continues to expand.

Because therapeutic antibody development is no longer the sole domain of pharmaceutical companies, we previously established the Toronto Recombinant Antibody Centre (TRAC), bringing together protein engineers, systems biologists, cell biologists and oncologists, with the goal of establishing a powerful pipeline to generate synthetic antibodies targeting cancer-associated markers on an unprecedented scale. Through the TRAC, Canada has established a strong foothold in antibody engineering and is poised to play a significant role in the future of the field.

In order for the benefits of the TRAC’s basic research platform to reach the medical, pharmaceutical and scientific communities, we recognized the need for a substantial investment in a dedicated commercialization strategy and formed the Centre for the Commercialization of Antibodies and Biologics (CCAB).

 

CCAB accessibility policy